Vanguard Group’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.45M | Buy |
291,277
+86,744
| +42% | +$959K | ﹤0.01% | 3495 |
|
|
2025
Q3 | $2.65M | Hold |
204,533
| – | – | ﹤0.01% | 3491 |
|
|
2025
Q2 | $2M | Buy |
204,533
+4,165
| +2% | +$43.9K | ﹤0.01% | 3533 |
|
|
2025
Q1 | $2.42M | Hold |
200,368
| – | – | ﹤0.01% | 3429 |
|
|
2024
Q4 | $3.08M | Hold |
200,368
| – | – | ﹤0.01% | 3438 |
|
|
2024
Q3 | $4.62M | Buy |
200,368
+6,621
| +3% | +$148K | ﹤0.01% | 3299 |
|
|
2024
Q2 | $3.75M | Sell |
193,747
-1,664
| -0.9% | -$44.6K | ﹤0.01% | 3373 |
|
|
2024
Q1 | $7.35M | Buy |
195,411
+90,094
| +86% | +$3.73M | ﹤0.01% | 3131 |
|
|
2023
Q4 | $3.18M | Buy |
105,317
+793
| +0.8% | +$17.3K | ﹤0.01% | 3443 |
|
|
2023
Q3 | $2.29M | Buy |
104,524
+231
| +0.2% | +$8.16K | ﹤0.01% | 3531 |
|
|
2023
Q2 | $4.05M | Sell |
104,293
-1,361
| -1% | -$120K | ﹤0.01% | 3402 |
|
|
2023
Q1 | $9.74M | Sell |
105,654
-39
| -0% | -$4.89K | ﹤0.01% | 2948 |
|
|
2022
Q4 | $15.1M | Buy |
105,693
+11,989
| +13% | +$2.99M | ﹤0.01% | 2762 |
|
|
2022
Q3 | $21.3M | Buy |
93,704
+16,503
| +21% | +$4.19M | ﹤0.01% | 2593 |
|
|
2022
Q2 | $18M | Buy |
77,201
+10,223
| +15% | +$2.24M | ﹤0.01% | 2687 |
|
|
2022
Q1 | $21.4M | Sell |
66,978
-10,968
| -14% | -$2.52M | ﹤0.01% | 2735 |
|
|
2021
Q4 | $21.8M | Buy |
77,946
+11,270
| +17% | +$1.93M | ﹤0.01% | 2792 |
|
|
2021
Q3 | $8.36M | Buy |
66,676
+375
| +0.6% | +$46.5K | ﹤0.01% | 3356 |
|
|
2021
Q2 | $10.9M | Buy |
66,301
+15,802
| +31% | +$3.22M | ﹤0.01% | 3156 |
|
|
2021
Q1 | $10.6M | Buy |
50,499
+27,740
| +122% | +$6.37M | ﹤0.01% | 3109 |
|
|
2020
Q4 | $5.12M | Buy |
22,759
+16,896
| +288% | +$3.46M | ﹤0.01% | 3344 |
|
|
2020
Q3 | $1.11M | Sell |
5,863
-556
| -9% | -$141K | ﹤0.01% | 3635 |
|
|
2020
Q2 | $1.54M | Sell |
6,419
-307
| -5% | -$60.3K | ﹤0.01% | 3507 |
|
|
2020
Q1 | $776K | Sell |
6,726
-233
| -3% | -$34.6K | ﹤0.01% | 3560 |
|
|
2019
Q4 | $1.16M | Sell |
6,959
-29
| -0.4% | -$14.7K | ﹤0.01% | 3601 |
|
|
2019
Q3 | $6.92M | Buy |
6,988
+897
| +15% | +$1M | ﹤0.01% | 3012 |
|
|
2019
Q2 | $6.96M | Buy |
6,091
+1,246
| +26% | +$1.13M | ﹤0.01% | 3052 |
|
|
2019
Q1 | $3.7M | Buy |
4,845
+2,193
| +83% | +$1.99M | ﹤0.01% | 3250 |
|
|
2018
Q4 | $2.56M | Buy |
2,652
+76
| +3% | +$100K | ﹤0.01% | 3297 |
|
|
2018
Q3 | $4.37M | Buy |
2,576
+68
| +3% | +$88.7K | ﹤0.01% | 3284 |
|
|
2018
Q2 | $2.57M | Buy |
2,508
+393
| +19% | +$423K | ﹤0.01% | 3421 |
|
|
2018
Q1 | $2.27M | Buy |
+2,115
| New | +$3.88M | ﹤0.01% | 3415 |
|
Other funds holding ACET
O
RCM
WP
PM
SCM
Vanguard Group's ACET Position: Q4 2025 in Review
Vanguard Group increased its Adicet Bio (ACET) stake by 42% in Q4 2025, buying an estimated $959K and bringing the position to 291,277 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #3495.
Vanguard Group first reported a position in ACET in Q1 2018 and has held it in 32 quarters since. The position peaked at $21.8M in Q4 2021. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.
- Vanguard Group held 291,277 shares of Adicet Bio worth $2.45M as of Q4 2025.
- Vanguard Group bought 86,744 Adicet Bio shares in Q4 2025, an estimated $959K.
- Adicet Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3495 holding.
- Vanguard Group first reported a position in Adicet Bio in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's Adicet Bio position peaked at $21.8M in Q4 2021.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.